TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jul 12, 2023 10:05 JST
Source:
Eisai
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
Including Lecanemab and Anti-MTBR Tau Antibody E2814, At The Alzheimer' s Association International Conference (AAIC) 2023
TOKYO, Jul 12, 2023 - (JCN Newswire) - Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI), and the company's investigational anti-MTBR** tau antibody, E2814, at the Alzheimer's Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023. Eisai will present data and research in eight oral and 19 poster presentations at the meeting. Two of the AAIC oral presentations will be presented as posters at the Alzheimer's Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.
"At AAIC 2023 Eisai will present the latest data on lecanemab, an anti-Aβ protofibril antibody, that recently received traditional approval in the U.S. for patients with mild cognitive impairment (MCI) due to AD and mild AD. Leqembi was studied in a broad population, which included a mix of racial and ethnic groups and patients with common comorbid conditions and concomitant medications. Additionally, Eisai will present important new data on E2814, an anti-MTBR tau antibody, which is currently in Phase II/III clinical trials with the Dominantly Inherited Alzheimer's Network Trials Unit at Washington University St. Louis," said Michael Irizarry, M.D., Deputy Chief Clinical Officer and Senior Vice President of Clinical Research, Alzheimer's Disease and Brain Health, Eisai Inc. "As part of Eisai's commitment to transparency and our human health care (hhc) and ecosystem mission, we will continue to present and publish data and information about our AD pipeline and research."
Key Eisai AAIC Presentations
- Amyloid Reduction and Evidence of Downstream Biomarker Modification Presentation of results
of Aβ, tau, neurodegeneration, gliosis, and imaging biomarkers in the Phase III Clarity AD study of
lecanemab (#80907)
- Drug Development in the Era of Anti-Amyloid Therapies Discussion of considerations in the
development of new drugs for AD and rational drug combinations based on pathophysiology (#70444)
- Subcutaneous Lecanemab is Predicted to Achieve Comparable Efficacy and Improved Safety Compared to Lecanemab IV in Early Alzheimer's Disease Presentation and discussion of results from studies to date on a subcutaneous formulation of lecanemab under development to potentially improve convenience and safety profile for patients (#82852)
- E2814: An Anti-Tau Therapy Engages its CNS Target and Affects the Downstream Tangle-Specific Biomarker MTBR-tau243 in Dominantly Inherited Alzheimer's Disease Report on the safety, pharmacokinetics, and biomarkers of anti-MTBR tau antibody E2814 in clinical trials in healthy adults and dominant inherited AD patients (#82771)
For the full press release, visit www.eisai.com/news/2023/pdf/enews202351pdf.pdf.
MEDIA CONTACTS:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@Eisai.com
Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia) EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
November 30 2023 15:25 JST
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
November 22 2023 08:28 JST
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
November 20 2023 16:05 JST
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
October 25 2023 19:43 JST
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 16 2023 13:07 JST
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
October 11 2023 12:07 JST
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
October 04 2023 18:08 JST
Eisai Launches New "Innovation" Page on Corporate Website
September 28 2023 16:05 JST
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
September 28 2023 13:49 JST
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
September 25 2023 14:17 JST
More Press release >>
Latest Press Release
Delica Mini Wins 2023-2024 Japan Car of the Year Design Award
Dec 08, 2023 21:07 JST
Space Compass, NTT DOCOMO, NTT and SKY Perfect JSAT to Develop Direct-to-Device Service via Space-based Non-terrestrial Network
Dec 08, 2023 17:34 JST
MHI and ADNOC Sign Agreement to Explore Low Carbon Collaboration Opportunities to Build Blue NH3 and Blue H2 Value Chains
Dec 08, 2023 17:22 JST
MHI and Mitsubishi Logisnext Receive First Order from Kirin Group for an Automated Picking Solution
Dec 08, 2023 17:09 JST
Macau LRT Barra Extension Line Begins Commercial Operations on December 8
Dec 08, 2023 17:07 JST
Fujitsu and Palantir to strengthen strategic partnership to solve societal challenges and accelerate business transformation globally
Dec 08, 2023 16:28 JST
Honda to Begin Sales of Refreshed Odyssey in Japan
Dec 07, 2023 16:30 JST
Honda to Premiere New EV Series for Global Markets at CES 2024
Dec 07, 2023 13:00 JST
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
Dec 07, 2023 11:00 JST
Hitachi High-Tech Launches Dark Field Wafer Defect Inspection System DI4600 to Provide High Throughput and High-Precision Defect Detection on Patterned Wafers
Dec 06, 2023 17:38 JST
Fujitsu optimizes installation of EV charging infrastructure in India with Fujitsu Fleet Optimization solution trial
Dec 06, 2023 11:02 JST
Fujitsu Finland to provide comprehensive IT services to Kempower, provider of electric vehicle fast charging solutions
Dec 05, 2023 10:52 JST
DENSO Announces Organizational and Executive Changes
Dec 04, 2023 18:12 JST
All-New Triton Earns Top Rating in 2023 ASEAN NCAP
Dec 04, 2023 17:07 JST
Fujitsu and KDDI Research successfully implement large-capacity multiband wavelength multiplexing transmission with installed optical fiber
Dec 04, 2023 10:34 JST
GC Collaborates with MHI to explore the utilization of hydrogen, ammonia and CCS technology to develop a large-scale petrochemical plant to achieve Net Zero
Dec 01, 2023 17:22 JST
NEC named among IAM's 2023 Asia IP Elite
Dec 01, 2023 14:50 JST
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 16:25 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised
Nov 30, 2023 16:17 JST
Olympus's Net-Zero Targets Approved by SBTi
Nov 30, 2023 11:00 JST
More Latest Release >>